Article

Development of a microcosting protocol to determine the economic cost of diagnostic genomic testing for rare diseases in Australia

2023-09-04

Abstract excerpt

<h4>Introduction</h4> Genomic testing is a relatively new, disruptive and complex health technology with multiple clinical applications in rare diseases, cancer and infection control. Genomic testing is increasingly being implemented into clinical practice, following regulatory approval, funding and adoption in models of care, particularly in the area of rare disease diagnosis. A significant barrier to the adoptio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f8593323-4139-5cdf-8d60-8bdb69ab8760
DOI: 10.1101/2023.09.04.23295012

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Development of a microcosting protocol to determine the economic cost of diagnostic genomic testing for rare diseases in AustraliaDOI 10.1101/2023.09.04.23295012Read

Standardising Workforce Cost Estimates Across Australian Jurisdictions: Genomic Testing as a Use CaseSemantic proximity Read

Micro-costing Diagnostics in Oncology: From Single-Gene Testing to Whole Genome SequencingSemantic proximity Read

Utilisation of subsidised genetic and genomic testing in a publicly funded healthcare system 2014–2023Semantic proximity Read

Continuing the sequence? Towards an economic evaluation of whole genome sequencing for the diagnosis of rare diseases in ScotlandSemantic proximity Read

Genomic test stewardship at scale: retrospective evaluation of a statewide public health serviceSemantic proximity Read

Is the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencingSemantic proximity Read

A cost analysis of a cancer genetic service model in the UKSemantic proximity Read

Costs of genetic testing: Supporting Brazilian Public Policies for the incorporating of molecular diagnostic technologiesSemantic proximity Read

“Jumping too far ahead”: Australian healthcare professional, scientist, and policy maker perspectives on using genomics in newborn screeningSemantic proximity Read

msJAMA. Genomics in medicine and public health: role of cost-effectiveness analysis.Semantic proximity Read

Cost of Goods Sold Analysis for Manufacturing mRNA-Based Cell and Gene TherapiesSemantic proximity Read

A decision analysis model for diagnostic strategies using DNA testing for hereditary haemochromatosis in at risk populations.Semantic proximity Read